The European medicines Agency’s (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause loss of vision.
Source: The Pharma Letter
This item was collected automatically from an official industry feed. Follow the source link for the complete announcement and primary documentation.